However, substantial heterogeneity has been observed across distinct tumor types and molecular subgroups, suggesting that rational combinations or sequential strategies co-targeting downstream MAPK/PI3K signaling or metabolic vulnerabilities may outperform FGFR monotherapy in delaying or overcoming resistance. This evidence concerns the gene PIK3CA and neoplasm.